DT-216P2 Shows Rapid Improvement in Friedreich Ataxia After Just 4 Weeks
Design Therapeutics’ DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects.
/ 4 items
#DSGN↓
Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
RBC Upgrades Design Therapeutics on Strong 2026 Outlook
RBC Capital upgrades Design Therapeutics to Outperform with a new $13 price target, citing promising 2026 milestones, positive data potential, and long-term revenue upside.